Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 13.58 |
| Open | 13.87 |
| Bid | 13.65 x 400 |
| Ask | 13.69 x 200 |
| Day's range | 13.38 - 13.91 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 1,050,773 |
| Market cap | 823.892M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.39 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.06 |
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Simply Wall St.Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Sage Therapeutics ( NASDAQ:SAGE ) First Quarter 2024 Results Key Financial Results Revenue: US$7.90m (up 140% from 1Q...
- GuruFocus.com
Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress
Revenue Beats Estimates, Losses Widen as Company Advances Brain Health Portfolio
© 2024 Yahoo. All rights reserved.